A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2022-12-29
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-02-22 (study day 35); relationship: not assessed
mild
assessed
Grade 1 Thrombocytopenia — outcome: UNKNOWN; onset 2023-04-01 (study day 73); relationship: not assessed
mild
assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-07-31 (study day 194); relationship: not assessed
Data queries
No data queries.